Newly in-licenced product should boost growth
​Solid interim results, demonstrating the resilience of its balanced portfolio. Alliance Pharma has emerged from a period of product-related headwinds with a stable core product range capable of modest growth and strong EBITA (25-30%) margins. Now, with two potentially significant growth opportunities, ambitions to internationalise the business model further and the borrowing facilities and discipline to transact on this stage, the outlook should be one of investor interest. As greater clarity over the timing of UK approval of Diclectin emerges, we are likely to raise our forecasts accordingly.
Alliance Pharma is a holding company. Co. is engaged in the acquisition, marketing and distribution of pharmaceutical and other medical products.
We are a rapidly growing, innovative corporate research & consultancy business, based in London, serving the needs of both public and private companies.
Our expert team of sector analysts and market professionals collectively have over 400 years of experience. This depth of knowledge and a reputation for integrity have built trust with investors. With effective communication and precision distribution, we help companies disseminate their investment message to interested investors, as well as advise them on strategy.
Our smaller, boutique structure allows us to provide first-class customer service and to deliver a wide range of ad-hoc services for multiple clients with different needs.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.